Finance

Lists
Why is MLYS up 2.02%?
Dive Deeper
MLYS:NASDAQ
Mineralys Therapeutics Inc
$20.71
+2.02%
(+0.41) 1D
Oct 19, 10:48:46 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLYS...
Open
$20.57
High
$21.05
Low
$20.27
Mkt. cap
1.83B
Avg. vol.
1.48M
Volume
109.42K
52-wk high
$47.65
52-wk low
$20.12
EPS
-$4.24
Beta
0.69
Shares outstanding
88.41M
No. of employees
76
Open
$20.57
High
$21.05
Low
$20.27
Mkt. cap
1.83B
Avg. vol.
1.48M
Volume
109.42K
52-wk high
$47.65
52-wk low
$20.12
EPS
-$4.24
Beta
0.69
Shares outstanding
88.41M
No. of employees
76
News stories
From web sources and news partners
About Mineralys Therapeutics Inc
CEO-
Employees76
Founded2019
Headquarters-
SectorBiotechnology
Websitemineralystx.com
Analyst ratings
Based on 7 analysts giving stock ratings to MLYS in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for MLYS in the last 3 months.
Highest
Current $20.71
$56.00 (+170.40%)
Average
$47.86 (+131.10%)
Lowest
$29.00 (+40.03%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Buy
Maintained
$49.00
+136.6%
10/12/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$56.00
+170.4%
10/12/2026
Unknown Analyst
UBS
Hold
Initiated
$29.00
+40%
10/11/2026
Alice Nettleton
UBS
Hold
Initiated
$29.00
+40%
10/12/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$52.00
+151.1%
08/12/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$40.00
+93.1%
08/12/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$55.00
+165.6%
08/12/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$55.00
+165.6%
08/12/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$54.00
+160.7%
08/12/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$52.00
+151.1%
05/07/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
$42.00
+102.8%
05/07/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
05/06/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
-$2.85 / -$0.54
-432.71%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
31.45M
24.40M
24.36M
221.38M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.68M
13.88M
20.98M
24.66M
Operating expense
41.13M
38.28M
45.34M
246.04M
Total operating expenses
41.13M
38.28M
45.34M
246.04M
Operating income
-41.13M
-38.28M
-45.34M
-246.04M
Other non operating income
4.00K
1.00K
5.00K
13.00K
EBT including unusual items
-36.93M
-32.23M
-39.34M
-241.07M
EBT excluding unusual items
-36.93M
-32.23M
-39.34M
-241.07M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36.93M
-32.23M
-39.34M
-241.07M
Net profit margin
-
-
-
-
Earnings per share
-0.52
-0.40
-0.47
-2.85
Interest and investment income
4.20M
6.04M
6.00M
4.96M
Interest expense
-
-
-
-
Net interest expenses
4.20M
6.04M
6.00M
4.96M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.12M
-38.27M
-45.33M
-246.04M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps